Clinical Report: Analysis of Acute and Long-Term Toxicity in Prostate Cancer Patients
Background
Prostate cancer is the most commonly diagnosed cancer among men in Colombia, and the use of hypofractionated radiotherapy has gained interest due to its potential advantages in treatment duration and patient convenience. However, comparative data on toxicity between MHRT and UHRT in Latin American contexts remain limited.
Data Highlights
No numerical data available in the source material.
Key Findings
The study reported acute grade >=2 genitourinary toxicity of 11.63% for UHRT and 25.17% for MHRT (p = 0.013).
In the PACE-C trial, acute grade >=2 genitourinary toxicity was 28% for UHRT and 27% for MHRT (p = 0.89).
Acute grade >=2 gastrointestinal toxicity was higher with UHRT at 17% compared to 10% for MHRT (p = 0.0011).
Baseline urinary medication use was significantly imbalanced, with 18.88% in the MHRT group and none in the UHRT group (p < 0.001).
The sample size for UHRT was smaller (86 patients) compared to MHRT (143 patients).
Technical delivery details emphasized the importance of rigorous preparation for UHRT, including daily image-guided radiotherapy.
Clinical Implications
The findings underscore the importance of considering baseline characteristics and treatment delivery methods when evaluating toxicity outcomes. Clinicians should be cautious in interpreting real-world data in light of randomized trial results.
Conclusion
The analysis presents important insights into the toxicity profiles of MHRT and UHRT in prostate cancer treatment, but highlights the need for careful interpretation of results due to potential confounding factors.
